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Rodolfo J Dennis1,3*, Dario Maldonado2†, Maria X Rojas3†, Pablo Aschner4†, Martin Rondón3†, Laura Charry3†,
Alejandro Casas2†
Abstract
Background: Inadequate glucose control may be simultaneously associated with inflammation and decreased lung
function in type 2 diabetes. We evaluated if lung function is worse in patients with inadequate glucose control,
and if inflammatory markers are simultaneously increased in these subjects.
Methods: Subjects were selected at the Colombian Diabetes Association Center in Bogotá. Pulmonary function
tests were performed and mean residual values were obtained for forced expiratory volume (FEV1), forced vital
capacity (FVC) and FEV1/FVC, with predicted values based on those derived by Hankinson et al. for Mexican-
Americans. Multiple least-squares regression was used to adjust for differences in known determinants of lung
function. We measured blood levels of glycosylated hemoglobin (HBA1c), interleukin 6 (IL-6), tumor necrosis factor
(TNF-a), fibrinogen, ferritin, and C-reactive protein (C-RP).
Results: 495 diabetic patients were studied, out of which 352 had inadequate control (HBA1c > 7%). After
adjusting for known determinants of lung function, those with inadequate control had lower FEV1 (-75.4 mL,
IC95%: -92, -59; P < 0.0001) and FVC (-121 mL, IC95%: -134, -108; P < 0,0001) mean residuals, and higher FEV1/FVC
(0.013%, IC95%: 0.009, 0.018, P < 0.0001) residuals than those with adequate control, as well as increased levels of
all inflammatory markers (P < 0.05), with the exception of IL-6.
Conclusions: Subjects with type 2 diabetes and inadequate control had lower FVC and FEV1 than predicted and
than those of subjects with adequate control. It is postulated that poorer pulmonary function may be associated
with increased levels of inflammatory mediators.
Background
The association of type 2 diabetes with decreased lung
function (measured by known determinants of pulmon-
ary disability and death, such as FEV1), has received
renewed attention [1,2]. Inflammation, microangiopathy,
and alterations in lung matrix proteins may all play a
role. The first mechanism tends to unify the impairment
seen in patients with emphysema with that seen in dia-
betes and cardiovascular disease; in this context, both
type 2 diabetes and chronic lung disease, such as
COPD, have been associated with increased levels of
low-grade acute and chronic systemic inflammatory
mediators and inflammatory markers [3-5]. Until
recently, however, few studies had explored lung func-
tion among subgroups of diabetic subjects. It is likely
that persistent inadequate glucose control over time
may alter regulation of inflammatory pathways that are
involved in the impairment of lung function [2,6].
It is still unknown if inadequate glucose control in
type 2 diabetes is simultaneously associated with a
decrease in lung function and increased systemic levels
of inflammatory markers. In this study, we compared
type 2 diabetes subjects based on their glucose control
profile (adequate vs. inadequate) and assessed differ-
ences in lung function (spirometry) and blood levels of
five known systemic inflammatory markers.
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Methods
This was a cross-sectional study. The sampling frame from
which patients were selected was the Colombian Diabetes
Association (ACD), a private institution in Bogota, Colom-
bia, that provides basic and specialized ambulatory care for
diabetic patients of all socio-economic strata. Patients
need not be referred with any special degree of severity or
case-mix. We invited to participate in the study both inci-
dent and prevalent diabetes patients of either sex, who
were seen at the ACD between July 2005 and September
2007. Inclusion criteria were age between 35 and 65 years,
and medical diagnosis of type 2 diabetes confirmed at
ACM. The Latin-American Diabetes Association (ALAD)
definition for type 2 diabetes (fasting glycemia equal to or
greater than 126 mgr/dL, glycemia equal to or greater
than 200 mgr/dL after a glucose load during a glucose tol-
erance test, or casual glucose blood levels of 200 mgr/dL
or more), is the standardized definition used in the ACD
[7]. We excluded patients that met any of the following
criteria: pregnancy, previous diagnosis of rheumatoid
arthritis or collagen disease; cystic fibrosis, lung cancer or
tuberculosis; thoracic, lung, or heart surgery; or deformi-
ties that would preclude conducting a reliable spirometric
procedure.
The study protocol was approved by the Clinical
Research Ethics Committee at Fundación Cardioinfantil
in Bogotá.
Sample size
Based on previous results comparing diabetic patients
against controls, we expected mean residual values larger
than -60 mL for the FEV1 [2] and mean standard devia-
tions between 100 ml and 250 ml in adults over 21 years
old [8]. With a type I error probability of 5% and a power
of 80%, we estimated a required sample size required of
500 subjects. The study included 495 subjects.
Data collection
A respiratory questionnaire, previously translated into
Colombian Spanish, and validated in other already pub-
lished research projects [9], was used for screening.
Once a case of type 2 diabetes was deemed as poten-
tially eligible, the subject was invited to participate and
to give informed consent. Baseline information was col-
lected by interview following a standardized data collec-
tion form. The participant was then given an
appointment for a second visit the next day for blood
sampling to measure fasting glucose, HBA1c, levels of
circulating inflammatory mediators and markers (IL-6,
TNF-a, Fibrinogen, Ferritin, C-RP). Spirometry was also
performed in the second visit, as well as height, weight
(barefoot and with lightweight indoor clothing), and
body-mass index measurements. The spirometer used
(Vitalograph, UK) met all American Thoracic Society
recommended criteria [10].
Blood samples were taken after a minimum of 6 hours
fasting (except insulin-dependent diabetics) using
vacuum tubes, centrifuged and processed on a daily basis
for glucose fasting levels, HBA1c, fibrinogen and ferritin,
following standard daily laboratory operating procedures.
A set of serum samples were stored at -20°C for a maxi-
mum of two months for other analyses. TNF-a, IL-6,
and high sensitivity C-RP were measured by a solid
phase, enzyme labeled, chemiluminescent sequential
inmunometric assay method, using the Immulite 1000
analyzer (EURO/DPC Ltd, Llanberis, UK). A total of
seven runs in batches were carried out during the course
of the study. Each run for C-RP, TNF and IL-6 was pro-
cessed in duplicate, and met standard specific control
assays provided by the manufacturer, two for TNF-a and
IL-6 (high and low), and three for C-RP (high, intermedi-
ate and low).
Data management and statistical analysis
Data collected was recorded in a previously designed
database using ACCESS (Office 2000). All statistical
analyses were performed with SAS software programs
(SAS Institute, NC). To assess the association of dia-
betes control as measured with HBA1c levels and mean
systemic values of inflammatory markers, we categorized
HBA1c values into equal or less than 7% and greater
than 7%, and tested for significance with the t-test. We
selected this cutoff point a priori because it is usually
selected in clinical practice to discriminate between
appropriate and inappropriate control [11], although
some patients may be optimally controlled at slightly
higher HbA1c values. A p value < 0.05 on a two-sided
test was considered significant. Bi-variate analyses
included the c2 test for categorical/nominal data, and
the independent t-test or its non-parametric equivalent.
Predicted FEV1, FVC and FEV1/FVC values adjusted for
age, sex and height were obtained for every subject,
based on the prediction equations obtained by Hankin-
son et al for Mexican-Americans [12], which have pro-
vided good fit to Colombian subjects, based on previous
studies by our group [13].
Residual values (observed minus predicted) were
obtained for FEV1, FVC and FEV1/FVC in each subject,
negative values representing lower than expected pul-
monary function. We also used least-squares multiple
linear regression models to further adjust mean residual
values for smoking history (current, past, none), body
mass index, exposure to indoor wood-smoke inhalation,
to assess the significance of interaction terms, and the
inclusion of inflammation markers. We also looked at
the association between glucose control, lung function
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and inflammatory markers, by stratifying HBA1c values




We screened 1888 subjects with history of type 2 dia-
betes and 495 were finally included in the study. The
most frequent cause for exclusion was age (outside the
stipulated inclusion criteria); past history of TB, lung
fibrosis, lung cancer, and thoracic trauma or surgery. Of
the 495 studied type 2 diabetic subjects, 352 (71%) were
classified as having inadequate control (HBA1c > 7%).
Table 1 shows the baseline characteristics of both
groups. There were no clinical or statistically significant
differences in sex, age, height, weight, exposure to cigar-
ette smoking or indoor wood smoke inhalation, chronic
lung disease or past clinical history of important cardio-
vascular co-morbidity. Those with inadequate glucose
control, however, had longer disease duration (9.07
years) than those with adequate glucose control (6.6
years, P = 0.0002).
Subjects with inadequate glucose control had lower,
unadjusted, FEV1 (- 90 mL) and FVC (-150 ml) that did
not reach statistical significance, and a somewhat higher
FEV1/FVC ratio (table 2). In general, there were no dif-
ferences in FEV1 and FVC between subjects with ade-
quate and inadequate glucose control (table 2). Subjects
with inadequate glucose control had lower FVC percent
predicted values (below 70%) (p = 0.02). There were no
differences between groups in the number of subjects
that would have been categorized as stage 1 obstruction
(GOLD) based on FEV1/FVC ratio < 70% (table 2).
With respect to mean systemic values of inflammatory
markers (table 3), TNF-a, fibrinogen, ferritin, and C-RP
were significantly higher in those with inadequate glu-
cose control than in those with adequate glucose control
(p < 0.05).
Relationship between glucose control and pulmonary
function
Table 4 shows the differences in pulmonary function
between subjects with adequate and inadequate control
after statistical adjustment for differences in anthropo-
metric characteristics and risk factor exposure (smoking
and wood smoke). Mean residual values for FVC were
significantly lower in those with inadequate glucose con-
trol than in those with adequate control (FVC difference
-121.2 mL; 95%CI: -134.1, -108.4; p < 0.0001). Similar find-
ings were seen in FEV1: those with inadequate glucose
control had lower values than those with adequate control
(difference -75.4 mL; 95%CI: -92.2, -58.6, p < 0.0001).
Those subjects with inadequate control also had greater
values of FEV1/FVC, (difference: 0.013; 95%CI: 0.009,
0.018, p < 0.0001).
Table 4 also shows mean residual values stratified by
categories of smoking history. There was a tendency to
have lower mean residuals with past or present exposure
to cigarette smoke, especially in those with inadequate
glucose control. No interaction term between BMI,
Table 1 SUBJECT CHARACTERISTICS (n (%), mean ± sd)
VARIABLE INADEQUATE CONTROL (n = 352) ADEQUATE CONTROL (n = 143) p VALUE
MALE SEX 169 (48.01) 75 (52.45) 0.3714
AGE (years) 53.21 ± 7.81 54.53 ± 7.61 0.0829
35-45 64 (18.18) 19 (13.29) 0.1037
46-55 140 (39.77) 54 (37.76)
56-65 148 (42.05) 70 (48.95)
HEIGHT (centimeters) 160.60 ± 10.40 161.42 ± 9.16 0.3865
WEIGHT (kilograms) 72.82 ± 14.43 73.80 ± 13.13 0.4689
SMOKING HISTORY 0.8750
non smoker 151 (42.90) 64 (44.76)
past smoker 152 (43.18) 58 (50.56)
current smoker 49 (13.92) 21 (14.69)
cigarettes/day 5.70 ± 5.86 7.14 ± 6.83 0.4026
median (p25-p75) 3.0 (2-7) 4.0 (2-10)
EXPOSURE TO DUST, LIFETIME 113 (32.10) 43 (30.07) 0.6594
EXPOSURE TO GASES, LIFETIME 48 (13.64) 22 (15.38) 0.6133
EXPOSURE TO WOODSMOKE, LIFETIME 100 (28.41) 32 (22.38) 0.1694
CHRONIC BRONCHITIS 8 (2.27) 3 (2.10) 0.9049
LUNG EMPHYSEMA 2 (0.57) 0 (0.00) 0.3659
ASTHMA 8 (2.27) 4 (2.80) 0.7312
PULMONARY EMBOLISM 0 (0.00) 0 (0.00)
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cigarette smoking status, and glucose control in their
joint effect on lung function was significant (data not
shown). The inclusion of all five inflammation markers
to the models did not significantly change results. The
only marker significantly associated with residual lung
function, after adjustment for all other variables in the
models, was C-RP (p = 0.04). Similarly, time elapsed
since diabetes diagnosis did not affect point estimates
for mean residual values of FEV1, FVC or FEV1/FVC.
Table 5 shows residual lung function and inflamma-
tion marker values by quintiles of HBA1c levels. There
was a trend towards lower lung function, especially for
FVC, and increased levels of inflammation as HBA1c
levels increased, especially for C-RP, ferritin and
fibrinogen.
Discussion
Results of this study show that those diabetic subjects with
inadequate glucose control over the past several weeks as
measured with HBA1c, have lower pulmonary function
than those with adequate control. These differences were
not explained by usual determinants of lung function such
as age, height, sex, cigarette smoking or other lifetime
exposures. Subjects with inadequate control also had sig-
nificantly higher levels of inflammatory markers (TNF-a,
ferritin, fibrinogen, and C-RP), although, there is no clear
dose-effect relation. We selected these markers, including
IL-6, because increased levels of these inflammatory cyto-
kines (IL-6 and TNF-a), as well as downstream proteins
such as C-RP, ferritin and fibrinogen, have been implicated
in the inflammatory response seen in COPD and diabetes.
The limitations of our approach should be discussed.
Although selection bias is a possibility, we minimized it
by selecting all consecutive cases with diabetes with no
particular severity of disease, duration, or case-mix.
Confounding bias is not likely in our study, as we
adjusted the results for known determinants of lung
function, such as age, height and sex, as well as smoking
history. Persistent confounding by smoking may be pos-
sible given that we did not quantify the intensity of life-
time exposure (i.e. pack-years). However, the likelihood
of this is low, because the intensity of current cigarette
exposure seemed to be lower in those with inadequate
control. Although those diabetic subjects with poorer
control also had longer disease duration, adjustment for
time elapsed from diagnosis did not change results.
Given that we assessed diabetes duration by patient his-
tory, however, we cannot exclude persistent confound-
ing and non-differential misclassification as a possible
explanation for this finding. Finally, by taking both inci-
dent and prevalent cases of diabetes, our results may be
confounded by the effects of treatment and by survivor
bias, but both biases, if present, would have tended to
decrease the magnitude of the effect sizes seen in this
study. Classification bias is not likely to have altered our
results, as all subjects met pre-determined criteria for
diabetes, and both the definition of control (HBA1c) and
cut-off point selected to define inadequate control
(greater than 7%) were established a priori. Some recall
bias may have been possible with respect to past medi-
cal history and respiratory exposures, but, even if pre-
sent, these are more likely to have been non-differential
between those with adequate and inadequate glucose
control (subjects were not aware of the hypothesis
under study).
From a clinical perspective, the importance of changes
in lung function has usually been judged as the rate of
change over time, derived from observational cohorts or
Table 2 PULMONARY FUNCTION (n (%), mean ± sd)
VARIABLE INADEQUATE CONTROL HBA1c >7% (n = 352) ADEQUATE CONTROL (n = 143) p VALUE
FEV1 (liters) 2.68 ± 0.73 2.77 ± 0.69 0.2080
FVC (liters) 3.36 ± 0.94 3.51 ± 0.86 0.0853
FEV1/FVC (%) 80.57 ± 6.50 79.21 ± 6.90 0.0447
FEV1 < 70% EXPECTED VALUE (*) 15 (4.26) 2 (1.40) 0.1133
FVC < 70% EXPECTED VALUE (*) 13 (3.60) 0 (0.00) 0.0200
FEV1/FVC < 70% EXPECTED VALUE (*) 17 (4.83) 11 (7.69) 0.2119
(*) Expected based on: Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care
Med 1999; 159: 179-187.
Table 3 INFLAMMATORY MARKERS (mean ± sd)
MARKER INADEQUATE CONTROL HBA1c >7% (n = 352) ADEQUATE CONTROL (n = 143) p VALUE
C-RP (mg/L) 2.75 ± 5.82 1.52 ± 2.01 0.0005
FERRITIN (ug/L) 163.05 ± 150.24 130.90 ± 114.87 0.0109
FIBRINOGEN (mg/dL) 444.09 ± 116.99 422.68 ± 98.23 0.0389
IL6 (pg/mL) 3.91 ± 3.65 3.56 ± 2.65 0.2399
TNF (pg/mL) 9.03 ± 5.35 7.98 ± 5.01 0.0390
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clinical trials. Thus, it is difficult to fairly assess the sig-
nificance of the magnitude of change observed in this
study, given the cross-sectional approach. This study
confirms previous findings of decreased lung function in
diabetic subjects and in those with insulin resistance
[2,6,14]. Davis et al and McKeever et al recently
reported decreased lung function in diabetic subjects,
and convincingly showed that this decrease is associated
with inadequate diabetes control, which is consistent
with our study results [6,15]. However, our study goes
further to show that some inflammatory markers are
elevated in patients with simultaneous inadequate con-
trol and decreased lung function, suggesting a potential
association. Mechanisms related to chronic hyperglyce-
mia may involve both the formation of oxygen radicals
and their effect on pulmonary vasculature or the alveo-
lar-capillary membrane, and the secondary effect of sys-
temic inflammation seen in diabetic patients [16-19];
both mechanisms need not be mutually exclusive. The
second mechanism tends to equate the impairment seen
in patients with emphysema with that seen in diabetes
and cardiovascular disease, through inflammatory med-
iators [20]. In addition to the wealth of literature avail-
able on endothelial damage and cardiovascular events,
recent studies have shown that systemic inflammation
markers such as ferritin [3], fibrinogen [21,22], and C-
RP are increased in subjects with type 2 diabetes as indi-
cators of prognosis, as well as inflammation mediators
associated with insulin resistance such as IL-1, IL-6, and
TNF-a [23].
Table 4 MEAN RESIDUAL PULMONARY FUNCTION (*) AND STRATIFICATION BY SMOKING HISTORY (**)
INADEQUATE CONTROL ADEQUATE CONTROL DIFFERENCE IN MEAN RESIDUALS
n Mean n Mean 95% CI
LL HL p Value
rFEV1 352 -164.9 143 -89.5 -75.4 -92.2 -58.6 < 0.0001
Smoking History
Non-smoker 151 -137.6 64 -57.1 -80.5 -95.9 -65.1 < 0.0001
Past 152 -181.5 58 -119.3 -62.2 -101.2 -23.0 0.0029
Current 49 -197.3 21 -105.8 -91.5 -173.6 -9.4 0.0194
rFVC 352 -247.3 143 -126.1 -121.2 -134.1 -108.4 < 0.0001
Smoking History
Non-smoker 151 -192.4 64 -130.8 -61.6 -74.0 -49.2 < 0.0001
Past 152 -294.1 58 -136.1 -158.0 -191.5 -124.4 < 0.0001
Current 49 -271.3 21 -83.7 -187.7 -245.4 -129.9 < 0.0001
rFEV1/FVC 352 1.021 143 1.008 0.013 0.009 0.018 < 0.0001
Smoking history
Non-smoker 151 1.024 64 1.023 0.001 -0.006 0.008 0.7473
Past 152 1.023 58 0.997 0.026 0.020 0.033 < 0.0001
Current 49 1.007 21 0.991 0.015 0.001 0.032 0.0184
(*) Values in bold are mean residuals for FEV1, FVC and FEV1/FVC adjusted for differences in age, height, sex, and smoking history.
(**) Values stratified by smoking history are mean residuals adjusted for differences in age, height, and sex.
CI: Confidence interval. LL: lower limit; HL: higher limit.
Table 5 QUINTILES OF HBA1c VALUES AND RELATION WITH RESIDUAL LUNG FUNCTION (*) AND MEAN
INFLAMMATORY MARKER LEVELS
1 2 3 4 5
< = 6.60 6.61-7.50 7.51 - 8.60 8.61 - 10.40 > 10.40
n = 107 n = 92 n = 103 n = 97 n = 96 p VALUE
rFEV1 (ml) -82.73 -96.05 -130.78 -224.63 -186.30 0.0848
rFVC (ml) -128.72 -133.01 -219.96 -314.23 -270.11 0.0324
C-RP 1.55 1.94 1.94 3.71 2.94 0.0155
FERRITIN 119.58 146.24 150.96 193.65 161.43 0.0056
FIBRINOGEN 424.89 420.60 444.27 438.56 461.67 0.0830
IL-6 3.55 3.71 3.88 4.03 3.88 0.8806
TNF 8.08 8.31 8.67 9.48 9.16 0.3050
(*) Mean residuals for FEV1 and FVC adjusted by differences in age, height, sex, and smoking history.
C-RP: C-reactive protein; TNF: Tumor necrosis factor.
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It should be highlighted that the impairment seen in
our study is more consistent with a restrictive lung dis-
order. Although not a uniform finding, this has been
previously described in other studies [1,24,25]. This sug-
gests a causal pathway (or pathways) for inflammation
different from that in emphysema and COPD. Alteration
of matrix proteins seen in DM due to the formation of
advanced glycosylation end products and subsequent
inflammation in the lungs [26] has been suggested, and
may provide such a pathway.
Conclusions
Diabetic subjects with inadequate glucose control have
lower pulmonary function than those with adequate
control, a difference not explained by usual determi-
nants of lung function. Similarly, those subjects with
inadequate control also had significantly higher levels of
inflammation markers (TNF-a, Ferritin, Fibrinogen, and
C-RP), suggesting a potential association. Our results
need to be confirmed by longitudinal studies (given that
diabetic control is a time-dependent variable). Hopefully,
it can also be shown that better glucose control can
result not only in no further decrease in lung function
but also in attenuation of the inflammatory response.
Our findings, however, should make clinicians more
aware of this association and add to the necessity of
advising diabetic patients of the need for adequate glu-
cose control.
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